Patient dies in phase 1 clinical trial of Bial’s drug in France
Bial said it is working with health authorities to understand the causes of this tragic and unfortunate situation. The yet to be named drug, believed to be BIA
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
Isomerase discovers and develops molecules that target peptidyl-prolyl isomerases including cyclophilins. The acquisition intends to further improve the collaboration between the firms and speed up NeuroVive’s research and